Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Free Cash Flow (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Free Cash Flow for 16 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 556.16% year-over-year to $19.2 million, compared with a TTM value of $33.1 million through Dec 2025, up 188.32%, and an annual FY2025 reading of $33.1 million, up 188.32% over the prior year.
  • Free Cash Flow was $19.2 million for Q4 2025 at Amicus Therapeutics, down from $35.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $35.3 million in Q3 2025 and bottomed at -$80.8 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$22.7 million, with a median of -$21.1 million recorded in 2021.
  • Peak annual rise in Free Cash Flow hit 556.16% in 2025, while the deepest fall reached 233.97% in 2025.
  • Year by year, Free Cash Flow stood at -$74.1 million in 2021, then decreased by 9.12% to -$80.8 million in 2022, then skyrocketed by 96.16% to -$3.1 million in 2023, then tumbled by 35.39% to -$4.2 million in 2024, then surged by 556.16% to $19.2 million in 2025.
  • Business Quant data shows Free Cash Flow for FOLD at $19.2 million in Q4 2025, $35.3 million in Q3 2025, and -$28.9 million in Q2 2025.